| abstract |
Novel single domain antibodies and antibody fragments specifically binding to PD-L1, and compositions comprising said antibodies or antibody fragments are provided. Nucleic acid encoding said antibodies or antibody fragments, host cells comprising same, and related use are further provided. Furthermore, therapeutic use and diagnostic use of said antibodies and antibody fragments are provided. In particular, combined therapy of these antibodies and antibody fragments with other therapies such as treatment methods or therapeutic agents is provided. |